Relation Therapeutics and GSK announce a research collaboration worth up to $110 million to generate human cellular datasets and train AI models, including the MORGAN platform, for drug target identification. The deal builds on a prior partnership targeting fibrotic diseases and osteoarthritis. GSK is expanding its artificial intelligence use and increasing research and development investments to boost its drug pipeline efficiency.
GSK-Relation AI drug discovery partnership
- ▪The collaboration between Relation Therapeutics and GSK builds on an earlier partnership focused on fibrotic diseases and osteoarthritis
- ▪Relation Therapeutics entered a research collaboration with GSK worth up to $110 million to generate human cellular datasets and train artificial intelligence models
AI-driven drug target identification
- ▪Relation Therapeutics will generate large-scale datasets showing how human cells respond to genetic and drug interventions to identify potential new drug targets
- ▪The datasets generated by Relation Therapeutics will be used to train artificial intelligence foundation models, including the MORGAN platform
GSK R&D investment strategy
- ▪GSK is increasing investment in research and development to strengthen the company's drug pipeline
- ▪GSK is expanding the use of artificial intelligence to improve the efficiency and success rate of drug discovery
Story comments
Loading comments…